CD274 and urothelial carcinoma: Specific monoclonal antibodies targeting the PD-1/PD-L1 signalling pathway have been used extensively in cancer immunotherapy, particularly in the treatment of metastatic melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, urothelial carcinoma, and Hodgkin lymphoma [17].